![](/img/cover-not-exists.png)
PCV68 POTENTIAL COST-EFFECTIVENESS OF A BIOMARKER TEST TO RECLASSIFY PATIENTS WITH AN INTERMEDIATE RISK BASED ON THE FRAMINGHAM RISK SCORE INTO A LOWER OR HIGHER CATEGORY TO OPTIMIZE STATIN THERAPY
LT Burgers, WK Redekop, JL SeverensVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72411-1
File:
PDF, 79 KB
english, 2010